KISS1R: Phase 1 Wet-Lab — KP-10 Reference + ncAA Leads C1-01, C1-02

Kiss1r: Phase 1 Wet-lab — Kp-10 Reference + Ncaa Leads C1-01, C1-02

KISS1

Peptide therapeutics — Fertility / Hypogonadism / KISS1R–GPR54 agonism

C1-01 (D-Tyr¹/Arg(Me)⁹) and C1-02 (Ac/D-Tyr¹/Thr⁵/azaGly⁷/Arg(Me)⁹) are ncAA-modified kisspeptin decapeptide agonists of KISS1R (GPR54) selected from the Generation 1 computational pipeline (PRODIGY-estimated Kd 0.64 nM and ~140 pM respectively). This Phase 1 wet-lab compares both leads against the natural-AA reference KP-10 (YNWNSFGLRF-NH2) at Adaptyv (BLI + NPFFR1/NPFFR2 selectivity counter-screens), with cAMP HTRF at Ginkgo on top binders and plasma-stability LC-MS on leads.

Description

Team

0x6a41b…b2173

Owner

Organisation

BIO Protocol

Experiment Cost

$10,000.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Kiss1r: Phase 1 Wet-lab — Kp-10 Reference + Ncaa Leads C1-01, C1-02

KISS1

Peptide therapeutics — Fertility / Hypogonadism / KISS1R–GPR54 agonism

Description

Team

0x6a41b…b2173

Owner

Organisation

BIO Protocol

Experiment Cost

$10,000.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Rationale

The project has conducted no experimental laboratory work whatsoever. All work to date consists exclusively of computational/in silico analyses including AI-driven structure prediction, molecular docking, binding free energy calculations, molecular dynamics simulations, and various predictive tools (proteolytic stability, solubility, immunogenicity, off-target screening). Gate 9, which represents the first wet-lab experimental validation step (BLI binding assays, cell-based functional assays, plasma stability), is planned but has not yet been initiated. The project therefore remains at the purely conceptual/computational stage with no empirical data.

Assessment

Low Confidence

RecommendationPROMOTE

Total Score4.45

Overall Assessment

This TRL 1 project scores 4.45/5.00, reflecting a very strong early-stage concept. The dominant contributor is the exceptional therapeutic relevance (score 5, weighted 3.0/3.0): the KISS1R mechanism is clinically validated by independent programs (MVT-602, TAK-683), the disease biology is well-understood with clear genetic causation, and the computational pipeline is unusually rigorous for this stage with a systematic 9-gate evaluation framework. The intellectual property position is strong (score 4, weighted 1.0/1.25), with novel multi-site modification strategies on the KP-10 scaffold, though prior art from existing clinical kisspeptin analogues and published modification data (Nishizawa 2012) introduces some competitive risk. Therapeutic optionality is the relative weakness (score 3, weighted 0.45/0.75), as the mechanism is fundamentally anchored to HPG axis biology and reproductive endocrinology, limiting diversification potential. Key risks at this stage include: (1) all data is computational — no experimental binding, functional, or stability data yet exists; (2) the NPFFR1 selectivity failure for C1-02 (ΔΔG -0.70 kcal/mol) represents a genuine pharmacological risk requiring experimental resolution; (3) C1-01 MD stability assessment is based on a single replica due to a technical artefact. The project is well-positioned for TRL advancement contingent on Gate 9 experimental validation outcomes.

Weighted Score

Therapeutic Relevance

The mechanism is highly scientifically plausible and targets a well-validated biological pathway. KISS1R (GPR54) is the obligate receptor for kisspeptin peptides that drive GnRH pulsatility via the HPG axis, and loss-of-function mutations in KISS1/KISS1R are directly causative of idiopathic hypogonadotropic hypogonadism (IHH). Clinical precedents (MVT-602 Phase I/II, TAK-683) independently validate KISS1R as a druggable target. The computational pipeline is rigorous (9-gate system with calibration against endogenous ligands and clinical compounds), and both lead candidates show exceptional predicted binding metrics (Kd 0.64 nM and ~140 pM) against a high-resolution cryo-EM structure (2.68 Å). The rational scaffold design addressing all four major proteolytic liabilities of native KP-10 demonstrates deep mechanistic understanding. The only caveat is that all data remains computational/in silico — Gate 9 experimental validation is planned but not yet executed.

Therapeutic Optionality

The KISS1R/kisspeptin system has moderate therapeutic optionality. The primary indication (IHH) is well-defined but relatively narrow (1 in 4,000–10,000 individuals). There is clear extension potential into broader fertility disorders (as demonstrated by MVT-602's clinical program in women with fertility disorders), and KISS1R expression in pituitary and gonadal tissues suggests potential applications in reproductive endocrinology more broadly. However, the mechanism is fundamentally tied to the HPG axis, limiting diversification into non-reproductive therapeutic areas. The library of 10 candidates (C1-01 through C1-10) with diverse modification strategies (PEGylation, cyclization, bivalent scaffolds) provides scaffold flexibility, but the target biology constrains therapeutic breadth. The concept does not readily extend to oncology, CNS, or metabolic disease in a straightforward manner.

Intellectual Property

The candidates incorporate novel combinations of non-natural amino acid modifications (D-Tyr1, Arg(Me)9, azaGly7, N-Ac cap, Thr5 substitution) applied to the KP-10 scaffold, which are likely patentable as novel chemical entities with specific structural claims. The specific combination of modifications and their rationale (simultaneous proteolytic protection at four sites plus potency enhancement) represents a differentiated approach. However, there is meaningful prior art risk: MVT-602 and TAK-683 represent existing clinical-stage kisspeptin analogues, and the Nishizawa 2012 publication on Arg(Me)9 modifications is in the public domain. The C-terminal RF-amide pharmacophore is a known structural motif shared with NPFF receptor ligands, which is well-characterized in the literature. The 10-compound library with diverse modification strategies (C1-03 through C1-10 including PEGylated, cyclic, fluorinated, and bivalent variants) provides IP breadth. Freedom-to-operate analysis relative to Myovant/Sumitovant and Takeda patent estates would be needed but is not discussed in the report. Score of 4 reflects strong novelty in specific modifications but acknowledged competitive landscape.